Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-10-23-Speech-2-462-750"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-10-23"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"lt"^^xsd:language2
lpv:document identification number	"en.20121023.45.2-462-750"2
lpv:hasSubsequent	lp_eu:2012-10-23-Speech-2-462-8752
lpv:speaker	lp:Juozas Imbrasas2
lpv:spokenAs	substitute; REGI (2012-01-19--2014-06-30)3 member; Delegation to the EU-Armenia, EU-Azerbaijan and EU-Georgia Parliamentary Cooperation Committees (2009-09-16--2014-06-30)3 member; EFD (2009-07-14--2014-06-30)3 member; TRAN (2012-01-19--2014-06-30)3 substitute; Delegation for relations with the Korean Peninsula (2012-02-15--2014-06-30)3 member; Delegation for relations with the countries of Southeast Asia and the Association of Southeast Asian Nations (ASEAN) (2009-09-16--2014-06-30)3 unknown; Partija Tvarka ir teisingumas (2009-07-14--2014-06-30)3 member; Delegation to the Euronest Parliamentary Assembly (2009-09-16--2014-06-30)3
lpv:translated text	"I voted in favour of this document because of the importance of the work of the European Medicines Agency in providing the EU Member States and institutions with scientific advise relating to the evaluation of the quality, the safety and the efficacy of medicinal products for human and veterinary use. The discharge is therefore a valid instrument of the European Parliament, which requires a decision based on factual and substantive arguments. It is felt that discharge can be granted to the European Medicines Agency in respect of the implementation of the EMA’s budget for the financial year 2010."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph